SuppreMol to Use Protagen Biomarker Panel | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German biopharma company SuppreMol will use Protagen's biomarker portfolio to identify markers that may be predictive of which patients may be the best candidates for SuppreMol's lead therapy systemic lupus erythematosus (SLE), the companies said today.

Under the agreement, SuppreMol will use Protagen's UNIarray technology platform in phase IIa clinical trials for a personalized therapy for SLE called SM101.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.